Univariate subgroup analysis of BX (Polgar reference)
| Group | % predicted FEV1 at 10 years intercept Best annual (All data) | % predicted FEV1 slope Best annual (All data) | ||
|---|---|---|---|---|
| *Between group interactions. | ||||
| Unknown | 73% (68%) | −1.4% (−0.7%) | p = 0.69 (p = 0.18)* | |
| Post-infectious | 51% (49%) | p = 0.02 | −0.8% (−0.3%) | |
| Primary immunodeficiency | 64% (58%) | (p<0.0001)* | −2.8% (−1.7%) | |
| Post-oncology | 74% (73%) | −2.4% (+0.7%) | ||
| Female | 71% (65%) | p = 0.18 (p = 0.31)* | −1.9% (−0.6%) | p = 0.96 (p = 0.51)* |
| Male | 63% (60%) | −1.9% (−1.1%) | ||
| Pacific ethnicity | 69% (65%) | p = 0.60 (p = 0.76)* | −0.9% (−1.0%) | p = 0.45 (p = 0.70)* |
| Maori ethnicity | 63% (59%) | −2.2% (−0.9%) | ||
| European ethnicity | 68% (61%) | −0.9% (−0.0%) | ||
| No chronic organism | 73% (68%) | p = 0.02 (p = 0.01)* | −2.2% (−2.1) | p = 0.41 (p = 0.41)* |
| Chronic H influenzae | 60% (54%) | −1.3% (−0.6) | ||
| Asthma | 63% (57%) | p = 0.16 (p = 0.08)* | −0.6% (−0.0) | p = 0.05 (p = 0.08)* |
| No asthma | 70% (66%) | −2.7% (−1.4) | ||